Infectious Disease

Incremental modifications in HCV screening and remedy can have an effect on populations in danger

December 04, 2020

1 min o’clock

Source / information

Source:

Adee M. Oral Abstract 43. Presented at: The Liver Meeting Digital Experience; 13-16 November 2020.

Disclosure:
Reau reports that he has served on advisory or review boards for AbbVie, Merck, Gilead and Intercept, serves on the boards of ABIM, advises for BMS and Gilead, receives grants or research support from GenFit and Gilead, and speaks for and teaches focus medicine and for CCO MedScape.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

In a model presented at The Liver Meeting’s Digital Experience, experts showed that incremental changes in hepatitis C screening and treatment strategies can positively impact populations at risk.

In the CDC collaboration experience, the NHANES population was compared to the non-NHANES population, which was reflected in a comparison between people with stable housing and those at higher risk for transient populations.

“In this population, they have demonstrated well that the care cascade has very little effect. The NHANES population had improvements in screening and association with care. The non-NHANES population recognized very little hepatitis C and, when recognized, traveled very little along the care cascade that would end in curative therapy, ”said Dr. Nancy S. Reau in an interview with Healio.

The speakers modeled how screening and treatment strategies can be modified to affect this population.

“Universal screening was imperative in all states, but universal screening doesn’t mean you screen all of them on Day 1. This universal screening strategy could be extended,” Reau said. “Annual screening rates didn’t have to be monumental to get an incredible level of recognition.”

Reau stated that even current treatment strategies under the guidelines are sufficient, but major changes may need to be made to meet WHO’s goals. The presented tool helped the states measure their individual strategies to best achieve the global goals of improved morbidity and mortality.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Take homes in HCV

Related Articles